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Abstract—Chemokine signaling has been implicated in the pathogenesis of diabetic neuropathy; however, the
role of chemokine CC motif receptor 4 (CCR4) remains unknown. The goal was to examine the function of
CCR4 in hypersensitivity development and opioid effectiveness in diabetic neuropathy. Streptozotocin (STZ;
200 mg/kg, intraperitoneally administered)-induced mouse model of diabetic neuropathy were used. An analy-
sis of the mRNA/protein expression of CCR4 and its ligands was performed by qRT-PCR, microarray and/or
Western blot methods. C021 (CCR4 antagonist), morphine and buprenorphine were injected intrathecally or
intraperitoneally, and pain-related behavior was evaluated by the von Frey, cold plate and rotarod tests. We
observed that on day 7 after STZ administration, the blood glucose level was increased, and as a conse-
quence, hypersensitivity to tactile and thermal stimuli developed. In addition, we observed an increase in
the mRNA level of CCL2 but not CCL17/CCL22. The microarray technique showed that the CCL2 protein level
was also upregulated. In naive mice, the pronociceptive effect of intrathecally injected CCL2 was blocked by
C021, suggesting that this chemokine acts through CCR4. Importantly, our results provide the first evidence
that in a mouse model of diabetic neuropathy, single intrathecal and intraperitoneal injections of C021 dimin-
ished neuropathic pain-related behavior in a dose-dependent manner and improved motor functions. More-
over, both single intrathecal and intraperitoneal injections of C021 enhanced morphine and buprenorphine
effectiveness. These results reveal that pharmacological modulation of CCR4 may be a good potential thera-
peutic target for the treatment of diabetic neuropathy and may enhance the effectiveness of opioids.  2020
The Author(s). Published by Elsevier Ltd on behalf of IBRO. This is an open access article under the CCBY license (http://crea-
tivecommons.org/licenses/by/4.0/).
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Diabetes mellitus is an epidemic of the 21st century, and
a recent report from the World Health Organization has
shown that since 1980, the number of adults living with
diabetes has nearly quadrupled to 422 million people
(WHO, 2017). One of the most common complications
is nerve impairment, which causes the development of
neuropathic pain (Feldman et al., 2017). The molecular
mechanisms involved in diabetic neuropathy are very
complex (Zychowska et al., 2013b; Feldman et al.,
2017); however, according to the latest research, cytokinehttps://doi.org/10.1016/j.neuroscience.2020.06.025
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77participation in this phenomenon is extremely important
(Zychowska et al., 2013b, 2015; Ji et al., 2014; Pop-
Busui et al., 2016; Rojewska et al., 2018). Recently, some
chemokines from the large cytokine family have been rec-
ognized as important factors that contribute to diabetic
neuropathy. It has already been suggested that chemoki-
nes belonging to three different subfamilies – XC: XCL1
(Zychowska et al., 2016), CC: CCL2 and CCL5 (Panee,
2012; Chou et al., 2016) and CXC: CXCL1, CXCL5,
CXCL9, and CXCL12 (Zychowska et al., 2015) – play
an important role in the development of diabetic neuro-
pathic pain. Additionally, among the CC subfamily,
CCL17 and CCL22 are also known to have pronociceptive
properties (Bogacka et al. 2020); however, their spinal
expression in nociception during diabetes has not been
studied thus far. The main target of CCL17 and CCL22
is chemokine CC motif receptor 4 (CCR4) (Yoshie and
Matsushima, 2015; Scheu et al., 2017); however,
according to the literature, this receptor probably has an
additional ligand with well-known pronociceptive proper-/licenses/by/4.0/).
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Therefore, the role of CCR4 in nociceptive transmission
needs to be studied, especially since current references
suggest chemokine receptors as promising targets for
neuropathic pain management. For example, some stud-
ies, including ours, have indicated that blockade of CC-
chemokine receptors, CCR1 (Pawlik et al., 2020), CCR2
(Kwiatkowski et al., 2017) and CCR5 (Matsushita et al.,
2014; Kwiatkowski et al., 2016; Piotrowska et al.,
2016a), attenuates the neuropathic pain symptoms
evoked by chronic constriction injury of the sciatic nerve
in rats. Moreover, in this model, CCR1, CCR2 and
CCR5 antagonists also enhance morphine effectiveness
(Kwiatkowski et al., 2016, 2017; Pawlik et al., 2020). How-
ever, to date, few pharmacological studies on the use of
chemokine antagonists have been performed in diabetic
neuropathy. In streptozotocin-induced diabetic neuropa-
thy, antagonists of CCR1 (Rojewska et al., 2018) and
CCR2 (Aye-Mon et al., 2018) diminish pain-related
behavior, in contrast to antagonists of CCR5 (Rojewska
et al., 2018).
Therefore, since diabetic neuropathy is a
neuroinflammatory disorder, in our opinion,
investigations should focus on the still undefined role of
the chemokine system. We hypothesized that CCR4 is
important for nociceptive transmission in diabetic
neuropathy and is as a consequence an interesting
pharmacological target for pain relief. Therefore, the aim
was to investigate changes in the spinal expression of
CCR4 and its ligands (CCL17, CCL22, and CCL2) in a
streptozotocin-induced mouse model of diabetic
neuropathic pain. Moreover, another aim was to
investigate whether C021, a CCR4 antagonist, is able to
block the pronociceptive properties of CCL2. The next
goal was to determine the dose-dependent effect of
single intrathecal and intraperitoneal injections of C021
on tactile and thermal hypersensitivity and motor
coordination in streptozotocin-treated mice.
Furthermore, this study also aimed to evaluate how
single intrathecal and intraperitoneal injections of C021
influence the analgesic effects of morphine and
buprenorphine in this model of diabetic neuropathic pain.EXPERIMENTAL PROCEDURES
Animals
All the experiments were performed on male Albino-Swiss
mice purchased from Charles River (Germany). The
animals (20–22 g) were housed in cages with sawdust
under a light/dark cycle of 12/12 h. Water and food were
available ad libitum. The experiments were carried out
according to the NIH Guide for the Care and Use of
Laboratory Animals and IASP recommendations
(Zimmermann, 1983). All the procedures were approved
by the II Local Ethics Committee on Animal Testing at
the Maj Institute of Pharmacology, Polish Academy of
Sciences (Krakow, Poland, LKE 75/2017, 1277/2015).
Care was taken to minimize animal suffering and reduce
the number of animals used in the experiments (3R
policy).Mouse model of diabetic neuropathic pain
Streptozotocin (STZ) is often used in experimental
studies (Kamei et al., 1991; Dogrul et al., 2011; Ohsawa
et al., 2011; Murakami et al., 2013) to induce diabetic neu-
ropathy by the specific necrosis of pancreatic beta cells
(Lenzen, 2008; Bishnoi et al., 2011). In our experiments,
a single intraperitoneal (i.p.) injection of STZ (200 mg/
kg; Tocris, Bristol, United Kingdom), dissolved in water,
was used to generate a model of type 1 diabetes
(Lenzen, 2008; Murakami et al., 2013; Zychowska et al.,
2015). As a control group, we used naive mice, which
were injected with water. Blood was collected from the tail
veins of the mice, and the glucose concentration was
measured with an Accu-Chek Active glucometer (War-
saw, Poland). The mice were considered diabetic when
the serum glucose levels were higher than 300 mg/dl at
day 7 after STZ injection.Pharmacological study
C021 dihydrochloride (C021, Tocris, Bristol, United
Kingdom); RS504393 (Tocris, Warsaw, Poland),
morphine hydrochloride (M; TEVA, Kutno, Poland);
buprenorphine (B; Polfa S.A., Warsaw, Poland) and
recombinant mouse CCL2 protein (R&D Systems,
Minneapolis, USA) were dissolved in V: water or DMSO
(only for RS504393) for injection. The control groups
were injected with water or DMSO at the same time
points. Substances were administered intrathecally (i.t.)
or intraperitoneally (i.p.). The i.t. injection was performed
using a Hamilton syringe with a thin needle, in
accordance with Hylden and Wilcox (Hylden and Wilcox,
1980) with later modifications (Fairbanks, 2003). The sub-
stances were injected into the lumbar region of the spinal
cord (between the L5-L6 vertebrae) in a volume of 5 ll.
CCL2 administration preceded by C021 injection: V or
C021 (30 lg/5 ll) were administered intrathecally. Then,
after 15 min, V or CCL2 (10 ng/5 ll) were injected i.t.
The behavioral tests were conducted 1 h after chemokine
injection. C021 or RS504393 injection in the STZ-induced
mouse model of diabetic neuropathic pain: V, CCR4
antagonist or CCR2 antagonist were administered
intrathecally (10, 20, or 30 lg/5 ll for C021 and 30 lg/5 ll
for RS504393) and intraperitoneally (1, 5, 10, or 20 mg/kg
for C021 and 30 lg/5 ll for RS504393) on day 7after STZ
treatment. The behavioral tests were conducted 1, 4 and
24 h after these injections. Coadministration of C021 with
opioids: V or CCR4 antagonist were administered i.t.
(30 lg/5 ll) and i.p. (10 mg/kg) on day 7 after STZ injec-
tion. Then, after 30 min, the V- and C021-treated mice
received a single injection of V, morphine or buprenor-
phine using the following doses: morphine: i.t.: 1 lg/5 ll;
i.p.: 5 mg/kg; buprenorphine: i.t.: 1 lg/5 ll; i.p.: 5 mg/kg.
The behavioral tests were conducted 30 min after the
administration of the opioids.Behavioral testsMeasurement of blood glucose levels and body
weight. The blood glucose concentrations and the body
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administration using an Accu-Chek Active glucometer
(Warsaw, Poland).
Tactile hypersensitivity (von Frey test). Tactile
hypersensitivity was evaluated using calibrated nylon
monofilaments of increasing strength (from 0.6 to 6 g)
(Stoelting, Wood Dale, USA). The mice were placed in
plastic cages with a wire net floor 5 min before the
experiment. The filaments were applied to the
midplantar surface of the hind paws until withdrawal
responses were observed (Zychowska et al., 2016;
Rojewska et al., 2018). Both hind paws were tested in
the same way in STZ-treated and naive mice.
Thermal hypersensitivity (cold plate test). The
reactions to thermal hypersensitivity were assessed
using the cold plate test (Ugo Basile, Gemonio, Italy).
The mice were placed on a cold plate with a
temperature of 2 C, and the latency to the elevation of
the hind paw was recorded (the cut-off latency was
30 s) (Zychowska et al., 2016; Rojewska et al., 2018). In
STZ-treated and naive mice, both hind paws were
observed simultaneously.
Motor coordination (rotarod test). The rotarod test is a
commonly used method to evaluate motor coordination in
animals by assessing their ability to move efficiently as
previously described (Starnowska et al., 2017). The mice
were placed in a separate compartment on a horizontal
rod that rotated at accelerating speed, starting at 2 rpm
and reaching 40 rpm within 300 s. The animals were accli-
mated to the apparatus and trained on the rotating rod.
The main experiment was performed after the training
sessions, which lasted 300 s each. The time until the mice
fell off the rod was recorded. A rotarod test was conducted
1 h after drug administration. The cut-off latency was
300 s.
mRNA and protein level analysis
The lumbar (L4–L6) regions of the spinal cord were
collected after the decapitation of naive mice and mice
with STZ-induced neuropathy on day 7.
Analysis of mRNA level (RT-qPCR). Total RNA was
extracted with TRIzol reagent (Invitrogen, Carlsbad,
USA) as previously described (Chomczynski and
Sacchi, 2006). The concentration and quality of the
RNA were measured byaDeNovixDS-11 Spectropho-
tometer (DeNovix Inc., Wilmington, USA). The Omniscript
RT Kit (Qiagen Inc., Hilden, Germany), oligo (dT16) pri-
mer (Qiagen Inc., Hilden, Germany) and RNAse inhibitor
(rRNasin, Promega, Mannheim, Germany) were used for
reverse transcription, which was performed using 1 lg of
total RNA. The obtained cDNA was diluted 1:10 with
RNase-/DNase-free H2O. RT-qPCR was conducted with
50 ng of cDNA from each sample using Assay-On-
Demand TaqMan probes (Applied Biosystems, Foster
City, USA) and was performed in an iCycler device
(Bio-Rad, Hercules, Warsaw, Poland). The following
TaqMan primers were used: Mm03024075_m1 (HPRT,hypoxanthine–guanine phosphoribosyl transferase);
Mm01244826_g1 (CCL17); Mm00436439_m1 (CCL22);
and Mm00441243_g1 (CCL2). As in our previous study,
HPRT was used as an endogenous control and an ade-
quate housekeeping gene (Kwiatkowski et al., 2019;
Pawlik et al., 2020). HPRT did not exhibit any significant
changes across groups.Analysis of protein level (Western blot). The samples
were homogenized in RIPA buffer containing a protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, USA) and
were cleared via centrifugation (30 min, 14,000 rpm, and
4 C). The total protein concentrations were measured
using the bicinchoninic acid (BCA) method. The
samples (10 lg of protein) were heated in loading buffer
(4 Laemmli buffer, Bio-Rad, Warsaw, Poland) for
5 min at 98 C. Electrophoresis was performed on
4–15% TGX precast polyacrylamide gels (Bio-Rad,
Warsaw, Poland). The proteins were transferred from
the gels (semidry transfer, 30 min, and 25 V) to Immun-
Blot PVDF membranes (Bio-Rad, Warsaw, Poland), and
the membranes were blocked for 1 h at room
temperature using 5% nonfat dry milk (Bio-Rad,
Warsaw, Poland) in Tris-buffered saline with 0.1%
Tween-20 (TBST). Next, the membranes were washed
in TBST buffer and incubated overnight at 4 C with the
following primary antibodies: rabbit anti-CCR4 (1:750,
Invitrogen, California, USA) and mouse anti-GAPDH
(1:5000, Millipore, Darmstadt, Germany). Then, the
membranes were washed with TBST buffer and
incubated for 1 h at room temperature with HRP-
conjugated secondary antibodies (Vector Laboratories,
Burlingame, USA) at a dilution of 1:5000. To dilute the
primary and secondary antibodies, the SignalBoostTM
Immunoreaction Enhancer Kit (Millipore, Darmstadt,
Germany) solution was used. The detection of the
selected proteins was performed using ClarityTM Western
ECL Substrate (Bio-Rad, Warsaw, Poland) and
visualized by Fujifilm LAS-4000 FluorImager system.
The relative levels of immunoreactivity were quantified
using Fujifilm MultiGauge software.Analysis of the protein level (RayBio mouse inflamma-
tion antibody array). The samples were homogenized in
1x Cell Lysis Buffer (RayBio, Peachtree Corners, GA,
USA) with a Protease Inhibitor Cocktail (Sigma-Aldrich,
St. Louis, USA) and were cleared by centrifugation
(30 min, 14,000g, and 4 C). The protein concentration
in the supernatant was determined using the BCA
Protein Assay Kit (Sigma-Aldrich, St. Louis, USA). Then,
the samples were diluted with 1 Blocking Buffer to a
final concentration of 250 lg protein per sample. The
RayBio membranes (Table 1) were blocked at room
temperature and incubated with 1 mL of sample
overnight at 4 C. Next, the samples were decanted,
and the membranes were washed three times with 2 mL
of 1 Wash Buffer I (RayBio, Peachtree Corners, GA,
USA) and two times with 2 mL of 1 Wash Buffer II
(RayBio, Peachtree Corners, GA, USA) at room
temperature. To each membrane, 1 mL of diluted biotin-
conjugated anti-cytokine antibodies (RayBio, Peachtree
Table 1. We used the RayBio Mouse Inflammation Antibody Array 1 (40) – CCL2 is referred to on the array as monocyte chemotactic protein 1
(MCP-1)
80 J. Bogacka et al. / Neuroscience 441 (2020) 77–92Corners, Georgia) were added and incubated at room
temperature for 90 min. Then, the primary antibodies
were decanted, and the membranes were washed. The
membranes were incubated for 2 h at room temperature
with 2 mL of 1000-fold diluted HRP-conjugated
streptavidin (RayBio, Peachtree Corners, GA, USA).
The HRP-conjugated streptavidin was decanted, and
the membranes were washed. The immunocomplexes
were detected using detection buffer (RayBio, Peachtree
Corners, GA, USA) and visualized using a Fujifilm LAS-
4000 FluorImager system. The relative levels of
immunoreactivity were quantified using Fujifilm Image
Gauge software.
Data analysis
For statistical analyses F test to compare variances was
performed. The behavioral and biochemical results on
Fig. 1 were statistically evaluated using a t-test or
Welch t-test (for single comparisons) depending on the
F test result. Moreover, one-way analysis of variance
(ANOVA) followed by Bonferroni’s post hoc test (for
multiple comparisons) were used to analyze the results
on Figs. 2–7. Obtained data are presented as means
± standard error of measurement (SEM). The total
number of mice for all experiments was 355 – a detailed
number of used animals is presented in figure legends.
All graphs were prepared using GraphPad Prism 7
software.
RESULTS
The influence of streptozotocin administration on
plasma glucose concentrations, neuropathic pain-
related behaviors, spinal CCL17, CCL22 and CCL2
mRNA levels and CCL2 and CCR4 protein levels
measured on day 7 after STZ treatment
An increase in the plasma glucose concentration was
observed on day 7 following a single STZ (200 mg/kg, i.
p.) injection compared with the plasma glucose
concentration in naive animals (t14.37 = 7.68,
p< 0.0001) (Fig. 1A). In addition, we observed the
development of tactile and thermal hypersensitivity, as
measured by the von Frey (t15.78 = 7.49, p< 0.0001)
and cold plate (t22.00 = 22.09, p< 0.0001) tests,
respectively (Fig. 1B, C). Moreover, we observed
significant changes in the CCL2 mRNA level
(t11.51 = 2.54, p= 0.0266) (Fig. 1D), but not in theCCL17 (Fig. 1E) and CCL22 (Fig. 1F) mRNA levels,
compared to those in naive mice. Additionally,
microarray analysis showed the upregulation of the
CCL2 protein level in the spinal cord (t15.57 = 3.56,
p= 0.0027) (Fig. 1G). Moreover, we demonstrated that
there were no changes in the levels of CCR4 in STZ-
treated animals compared to this in naive mice, as
measured by Western blot analysis (Fig. 1H).The effect of a single intrathecal administration of
recombinant CCL2 protein preceded by the injection
of C021 in naive mice.
Our results indicated that a single intrathecal injection of
C021 (30 lg/5 ll; Fig. 2A) had no effect on tactile and
thermal hypersensitivity, as measured by the von Frey
(Fig. 2B) and cold plate (Fig. 2C) tests, 1 h after
administration. We observed strong tactile and thermal
hypersensitivity 1 h after the injection of CCL2, as
measured by the von Frey (F3,20 = 19.27, p< 0.0001)
(Fig. 2B) and cold plate (F3,20 = 20.67, p< 0.0001)
(Fig. 2C) tests, respectively. The injection of C021
(30 lg/5 ll) 15 min before the intrathecal injection of
recombinant CCL2 protein prevented the chemokine-
induced hypersensitivity observed in the von Frey and
cold plate tests (Fig. 2B, C).The influence of a single intrathecal injection of C021
or RS504393on the neuropathic pain-related behavior
measured on day 7 after STZ administration
We observed in the von Frey test that C021 administered
intrathecally (10, 20, or 30 lg/5 ll; Fig. 3A) diminished the
tactile hypersensitivity measured 1 h (F3,27 = 12.77,
p< 0.0001) and 4 h (F3,28 = 4.60, p< 0.0097) after
injection compared with that in the V-treated group
(Fig. 3A). This effect was still observed 24 h after the
administration of a dose of 30 lg/5 ll. In the cold plate
test, the intrathecal administration of C021 significantly
reduced the thermal hypersensitivity 1 h (F3,27 = 12.77,
p< 0.0001) and 4 h (F3,28 = 4.60, p< 0.0097) after
injection compared with that in the V-treated group
(Fig. 3B). The effect lasted 24 h for doses of 20 and
30 lg/5 ll. We observed that RS504393 administered
intrathecally (30 lg/5 ll) did not influence tactile and
thermal hypersensitivity, as measured 1, 4 and 24 h
after injection, compared with that in the V-treated group
(Fig. 3C D).
Fig. 1. Changes in the pain-related behavior caused by hyperglycemia together with the
changes in the spinal mRNA levels of CCL2, CCL17 and CCL22 and in the protein levels of
CCL2 and CCR4 7 days after STZ treatment in mice. The effects of a single STZ injection on
plasma glucose (A), mechanical (von Frey test; B) and thermal (cold plate test; C) hypersensitivity,
mRNA levels of CCL2 (D), CCL17 (E) and CCL22 (F) (RT-qPCR analysis) and protein levels of CCL2
(G, protein microarray analysis) and CCR4 (H, Western blot analysis). Data are presented as the fold
change relative to control mice (naive) ± SEM, total number of animals: 66 mice: A–F, naive, n= 7–
12 mice per group; STZ, n= 12 mice per group; G, naive, n= 12 mice per group; STZ, n= 12 mice
per group and H, naive, n= 8; STZ, n= 10 mice per group. The results were statistically evaluated
using t-test; #<0.05; ##p< 0.01; ###p< 0.001 indicate changes compared with naive mice.
Abbreviations: N, naive; STZ, streptozotocin.
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on the effectiveness of morphine and buprenorphine
measured on the 7th day after STZ treatment
A single intrathecal C021 injection (30 lg/5 ll; Fig. 4A)
significantly attenuated the STZ-induced tactile
hypersensitivity, as measured by the von Frey test
(F3,24 = 52.03, p< 0.0001 Fig. 4B; F3,25 = 59.87,
p< 0.0001 Fig. 4D), compared to that in the V-treated
group. Similarly, in the cold plate test, we observed a
reduction in thermal hypersensitivity in the C021-treated
mice (F3,26 = 144.30, p< 0.0001 Fig. 4C;
F3,26 = 232.90, p< 0.0001 Fig. 4E). Tactile and
thermal hypersensitivity were also significantly reduced
after a single i.t. injection of morphine (1 lg/5 ll) or
buprenorphine (1 lg/5 ll), as measured by the von Frey
(Fig. 4B, D) and cold plate tests (Fig. 4C, E). The
intrathecal injection of C021 enhanced the effectivenessof both morphine and
buprenorphine in the von Frey
(Fig. 4B, D) and cold plate tests
(Fig. 4C, E).The influence of single
intraperitoneal injection of C021
or RS504393 on neuropathic
pain-related behavior on the 7th
day after STZ treatment
We observed in the von Frey test
that C021 administered
intraperitoneally (1, 5, 10, or
20 mg/kg; Fig. 5A) diminished
tactile hypersensitivity 1 h
(F4,32 = 30.52, p< 0.0001) after
treatment in a dose-dependent
manner. The effect was not
observed after 4 h. In the cold
plate test, the most effective
intraperitoneal doses were 10 and
20 mg/kg, and these doses led to
the attenuation of thermal
hypersensitivity 1 h (F4,32 =
48.06, p< 0.0001) after injection
(Fig. 5B); however, this effect was
not observed after 24 h for both
doses. We revealed that the
intraperitoneal injection of
RS504393 (10 lg/kg) did not
affect tactile and thermal
hypersensitivity, as measured 1, 4
and 24 h after injection, compared
with that in the V-treated group
(Fig. 5C, D).The effect of a single
intraperitoneal injection of C021
on the effectiveness of
morphine and buprenorphine
measured on the 7th day after
STZ treatment
A single intraperitoneal injection of
C021 (10 mg/kg; Fig. 6A)significantly attenuated the STZ-induced tactile
hypersensitivity 1 h after administration, as measured by
the von Frey test (F3,27 = 60.54, p< 0.0001 Fig. 6B;
F3,22 = 71.55, p< 0.0001 Fig. 6D), compared to that in
the V-treated animals. Likewise, we observed a
reduction in thermal hypersensitivity in the cold plate
test (F3,24 = 56.73, p< 0.0001 Fig. 6C; F3,21 = 154.10,
p< 0.0001 Fig. 6E). Hypersensitivity was also
significantly diminished after a single i.p. injection of
morphine (5 mg/kg) or buprenorphine (5 mg/kg), as
measured by the von Frey (Fig. 6B, D) and cold plate
tests (Fig. 6C, E). The intraperitoneal injection of C021
enhanced the effectiveness of both morphine and
buprenorphine in the von Frey (Fig. 6B, D) and cold
plate tests (Fig. 6C, E).
Fig. 2. The pronociceptive effect of a single intrathecal injection of CCL2 diminished by the
previous intrathecal injection of C021 in naive mice. Behavioral tests were performed 1 h 15 min
after V or C021 (30 lg/5 ll) treatment, which means 1 h after CCL2 (10 ng/5 ll) administration A.
Tactile (B, von Frey test) and thermal (C, cold plate test) hypersensitivity was measured. Data are
presented as the mean ± SEM, total number of animals: 24 mice: (B, C) n= 6 mice per group. The
results were evaluated with the use of one-way ANOVA followed by Bonferroni’s multiple comparisons
post hoc test of selected pairs at the indicated time points. ooop< 0.001 indicates differences between
the V + V and V + CCL2-treated naive mice; ^^^p< 0.001 indicates differences between the V
+ CCL2- and C021 + CCL2-treated naive mice. Abbreviations: C021, C021 dichydrochloride (CCR4
antagonist); N, naive; V, water for injection.
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injection of C021 on motor coordination measured on
the 7th day after STZ treatment
A single intrathecal (30 lg/5 ll; Fig. 7A) and
intraperitoneal (10 mg/kg; Fig. 7B) C021 injection
significantly improved motor coordination in STZ-treated
animals, as measured by the rotarod test, while V-
treated mice exhibited significant impairment of motor
function compared with naive animals (F2,29 = 6,70,
p= 0.0040 for i.t and F2,21 = 4.54, p= 0.0230 for i.p.).DISCUSSION
The present study is the first to demonstrate the
importance of CCR4 as one of the crucial receptors
involved in the pathogenesis of neuropathic pain in
diabetes. In a STZ-induced mouse model of diabetic
neuropathy, we proved that the mRNA and protein
levels of CCL2 are elevated in the spinal cord on day 7,
when strong tactile and thermal hypersensitivity has
developed. Moreover, in naive mice, the CCR4
antagonist is able to block the pronociceptive properties
of intrathecally injected CCL2. Importantly, our research
provides the first evidence that in STZ-induced
neuropathy, both the intrathecal/intraperitonealadministration of C021 (CCR4
antagonist) diminishes tactile and
thermal hypersensitivity in a dose-
dependent manner, beneficially
effects motor coordination, and
enhances the analgesic properties
of morphine and buprenorphine.
Our results provide a novel basis
for the further evaluation of the
potential use of CCR4 as a target
for the treatment of diabetic
neuropathy and suggest spinal
CCL2/CCR4 signaling as an
important process for diabetic
neuropathy development and
opioid effectiveness.
Streptozotocin-induced
diabetes is a well-established
animal model used in studies of
neuropathic pain (Morgado et al.,
2011; Pabreja et al., 2011;
Zychowska et al., 2015, 2016,
2017; Castany et al., 2016; Kou
et al., 2016; Rojewska et al.,
2018). The hyperglycemic states
that occur in diabetes are responsi-
ble for Schwann cell metabolic
activity disruption and myelin
degeneration and, consequently,
neuropathic pain development
(Mizisin, 2014). The response to
noxious stimuli is transmitted by
lightly myelinated Ad and unmyeli-
nated C fibers, while the reaction
to nonnoxious stimuli is conducted
by highly myelinated Ab fibers
(Neumann et al., 1996). Moreover,high blood glucose level contributes to the development of
inflammation. The release of inflammatory mediators,
such as interleukins and chemokines, initiates the
immune response. The neuroinflammatory process at
the spinal cord level can cause the activation of glial cells,
which can release many pronociceptive factors in an
uncontrolled manner. In summary, the pathophysiology
of diabetic neuropathic pain is complex and includes
peripheral and central neuronal changes as well as neu-
roimmune interactions, which become more prominent
during inflammatory reactions (Safieh-Garabedian et al.,
2019). In streptozotocin-induced diabetes, the increased
blood glucose concentration correlates with long-lasting
hypersensitivity to mechanical and thermal stimuli
(Zychowska et al., 2013a), and this correlation is in agree-
ment with our obtained results. Currently, an increasing
number of works indicate the important role of neuroim-
munological changes in neuropathy development
(Zychowska et al., 2013a, 2015; Rojewska et al., 2018);
however, the role of CCR4 in diabetes still needs to be
clarified, which is why this receptor became the subject
of our research.
There is growing evidence that suggests the
functional involvement of the CCR4-CCL17/CCL22/
Fig. 3. The intrathecal injection of C021 diminished hypersensitivity in a dose-dependent
manner 7 days after STZ treatment in mice. Effects of single injections of V, C021 or RS (C021: 10,
20, or 30 lg/5 ll; RS: 30 lg/5 ll) on mechanical (von Frey test; A, C) and thermal (cold plate test; B, D)
hypersensitivity, as measured at 1, 4 and 24 h following antagonist injection. Data are presented as the
mean ± SEM, total number of animals: 52 mice: (A, B) n= 6–8 mice per group; (C, D) n= 9–10 mice
per group. The results were evaluated using one-way ANOVA followed by Bonferroni’s test for multiple
comparisons. *p< 0.05, **p< 0.01, and ***p< 0.001 indicate significant differences between the V-
treated and C021-treated STZ-exposed animals. Abbreviations: V, water for injection or DMSO
(control group for RS504393); C021, C021 dichydrochloride (CCR4 antagonist); RS, RS504393
(CCR2 antagonist); STZ, streptozotocin.
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significance of CCR4 during the development of asthma
(Zhang et al., 2017), multiple sclerosis (Moriguchi et al.,
2016; Jafarzadeh et al., 2017; Ruland et al., 2017;
Scheu et al., 2017), and dermatitis (Matsuo et al., 2018)
has been described. Recently it has been shown that
blockade of the CCR4 might be a promising strategy in
patients with hepatocellular carcinoma (Cheng et al.,
2017), glioblastoma (Jacobs et al., 2010), prostate, ovar-
ian, lung and breast cancers (Zou et al., 2005; Li et al.,
2012; Maolake et al., 2017). It has been indicated that
CCR4 promotes tumor growth and metastasis (Cheng
et al., 2017). Moreover, in vitro data have shown that
CCL2 not only increases the expression of CCR4 in can-
cer cells (Maolake et al., 2017), but also induces the
migration of lymphocytes toward melanoma (Zhang
et al., 2006). In 2017, Kiguchi et al. showed for the first
time altered spinal expression of CCR4 in diabetic mon-
keys; however, the role of CCR4 in nociceptive transmis-
sion has not been studied thus far (Kiguchi et al., 2017).
CCR4 is present in many cells of the nervous system,
including both neuronal (Meucci et al., 1998) and non-
neuronal (e.g. microglia, astroglia, dendritic cells, macro-
phages, lymphocytes, basophils, natural killer cells, and
platelets) (Abi-Younes et al., 2001; Flynn et al., 2003;
Stolberg et al., 2011; Pease and Horuk, 2014) cells.
CCR4 has two main ligands, CCL17 and CCL22 (Imaiet al., 1997; Yoshie and
Matsushima, 2015; Scheu et al.,
2017), which, as we have shown,
exhibit strong pronociceptive prop-
erties in naive mice (Bogacka
et al., 2020). CCL17 can be pro-
duced by microglia (Klein et al.,
2017), thymus and peripheral
blood mononuclear cells (Imai
et al., 1997; Nomiyama et al.,
1997), dendritic cells (Sallusto
et al., 1999; Alferink et al., 2003)
and neurons (Fülle et al., 2018).
The level of CCL17 is enhanced
in patients suffering from
fibromyalgia (Garcia et al., 2014),
diabetic retinopathy (Dai et al.,
2014) and in animal models of
multiple sclerosis (Ruland et al.,
2017; Scheu et al., 2017). CCL22
is mainly released by macro-
phages and microglia (Yamashita
and Kuroda, 2002; Scheu et al.,
2017), and increased levels of
CCL22 have been described in
animal models of asthma (Zhang
et al., 2017), dermatitis (Matsuo
et al., 2018) and multiple sclerosis
(Moriguchi et al., 2016; Ruland
et al., 2017). However, at the
spinal cord level, we did not
observe changes in the mRNA
levels of CCL17 and CCL22 after
streptozotocin administration, so
it seems that their central role isnot crucial in mouse models of diabetes. However, in
the periphery, the importance of CCL17 and CCL22 dur-
ing tissue repair in diabetes was recently proven (Barros
et al., 2019). Around 80% of people with diabetes suffer
from a various skin disorders (Demirseren et al., 2014).
Wound healing is a process that involves many inflamma-
tory mediators and is one of the serious long-term compli-
cations associated with this metabolic disease. In 2019,
Barros et al. showed that the CCR4/CCL17/CCL22 axis
is engaged in regulatory T cell recruitment and activation
in inflamed skin. The results of that study provide evi-
dence that CCR4/ diabetic mice displayed an increase
in collagen fiber deposition (Barros et al., 2019). However,
there are evidences that CCR4-deficient mice are prone
to autoimmune disorders because thymocytes do not
undergo efficient clonal deletion and, as a consequence,
autoreactive T cells are accumulated in the periphery
(Hu et al., 2015). Therefore, it is necessary to have in
mind that CCR4 blockade, except significant analgesic
benefits and promotion of wound healing process under
diabetic neuropathy, may act like a double-edged sword.
In reference to T cells importance, CCR4 is expressed
by Th2 cells and it is worth to mention that diabetes can
be mediated by Th1 (Von Herrath and Oldstone, 1997),
Th2 (Anderson et al., 1993) or both Th1/Th2 cells (Azar
et al., 1999). These populations are known to be
Fig. 4. The single intrathecal injection of C021 enhanced the effectiveness of morphine and
buprenorphine 7 days after STZ treatment in mice. Animals treated with a single injection of V or C021
(30 lg/5 ll) received a single dose of V, M (1 lg/5 ll) or B (1 lg/5 ll) after 30 min, and 30 min later, the
behavioral tests were conducted. Data are presented as the mean ± SEM, total number of animals:
54 mice: (B, C) n= 6–8 mice per group; (D, E) n= 6–8 mice per group. The results were analyzed
using one-way ANOVA with Bonferroni’s multiple comparisons test. ***p< 0.001 indicates changes
compared with the V + V-treated STZ-exposed mice; @@@p< 0.001 indicates differences between
the C021 + V- and C021 + M/B-treated STZ-exposed mice; +++p< 0.001 indicates differences
between the V +M/B- and C021 + M/B-treated STZ-exposed mice. Abbreviations: B; buprenor-
phine; C021, C021 dichydrochloride (CCR4 antagonist); M, morphine; STZ, streptozotocin; V, water
for injection.
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gression of the diabetes, mostly
because of disrupted balance of
their regulatory cytokines (Azar
et al., 1999). Accordingly, it might
seem that blockade of CCR4 in
Th2 cells could have a negative
effect under diabetes, since this
cells were generally regarded as
anti-inflammatory. However, Th2
and their mediators were shown
to be involved in pathogenesis of
diabetes through support of pan-
creatic mononuclear-cell infiltration
and acceleration of b islet cell
destruction (Azar et al., 1999).
Therefore it is possible, that
CCR4 blockade in diabetes would
also help to restore balance
between Th1/Th2 mediators.
Besides, in progression of neu-
ropathy an increasing role has
been attributed to microglia and
macrophages cells. What is signifi-
cant to mention, CCR4 can be also
expressed by those cells (Flynn
et al., 2003). It is currently known
that microglia is important in the
development of diabetic neuro-
pathic pain (Zychowska et al.,
2016). Moreover, in our previous
study we have shown that C021
administration can decrease level
of IBA-1-positive cells both in cen-
tral and peripheral nervous system,
what leads to decrease of painful
symptoms evoked by chronic con-
striction injury (Bogacka et al.,
2020). This results additionally
support our hypothesis that block-
ade of CCR4 on microglia may
have beneficial effect in the treat-
ment of diabetes-based
neuropathy.
It seems that another important
ligand for CCR4 is CCL2, which
until now, was considered to be
the main ligand of CCR2. CCL2 is
a key chemoattractant molecule
for leucocytes, and it principally
recruits monocytes and, to a
lesser extent, memory T cells and
dendritic cells to the sites of
inflammation (Graves et al., 1999;
Sorensen et al., 2004; Deshmane
et al., 2009; McMillin et al., 2014).
After sciatic nerve ligation in rats,
the repeated intrathecal adminis-
tration of a CCR2 antagonist effec-
tively reduced neuropathic pain
symptoms (Kwiatkowski et al.,
Fig. 5. Intraperitoneally injected C021 diminished hypersensitivity in a dose-dependent
manner 7 days after STZ treatment in mice. Effects of a single injection of V, C021 or RS (C021:
1, 5, 10, or 20 mg/kg; RS: 10 mg/kg) on mechanical (von Frey test; A, C) and thermal (cold plate test;
B, D) hypersensitivity, as measured at 1, 4 and 24 h following antagonist administration. Data are
presented as the mean ± SEM, total number of animals: 60 mice: (A, B) n= 5–8 mice per group; (C,
D) n= 7–10 mice per group. The results were evaluated using one-way ANOVA followed by
Bonferroni’s test for multiple comparisons. *p< 0.05, **p< 0.01, and ***p< 0.001 indicate
significant differences between the V-treated and C021-treated animals after treatment with STZ.
Abbreviations: V, water for injection or DMSO (control group for RS504393); C021, C021
dichydrochloride (CCR4 antagonist); RS, RS504393 (CCR2 antagonist); STZ, streptozotocin.
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Moreover, in a model of osteoarthritis, CCR2-knockout
mice still had transient distal mechanical hypersensitivity
(Miller et al., 2012). Importantly, single intrathecal and
intraperitoneal injections of a CCR2 antagonist, in con-
trast to injections of a CCR4 antagonist, do not relieve
hypersensitivity in diabetes. A few studies suggested that
CCL2 also induced effects through CCR4 (Graves et al.,
1999; McMillin et al., 2014), which is in agreement with
our behavioral results showing that the CCR4 antagonist
can partly diminish the CCL2 pronociceptive properties
after its intrathecal administration in naive mice. In the
diabetic model, we demonstrated the spinal upregulation
of CCL2, which is why this chemokine seems to be an
important mediator of nociceptive transmission via
CCR2 and CCR4. Our data provide evidence that even
a single intrathecal injection of C021 can effectively dimin-
ish pain-related behavior on day 7 of STZ-induced neu-
ropathy in mice, when we observed fully developed
hypersensitivity. Furthermore, a single intraperitoneal
injection of C021 successfully diminished the neuropathic
pain-related symptoms in diabetic neuropathy. Interest-
ingly, our results provide proof that in diabetes, CCR4
blockade is more effective than CCR2 blockade. It is
known that during diabetes, the deterioration of various
motor skills can be observed (Pfützner et al., 2011).
Importantly, patients with this disease show slowerwalking velocity and shorter stride
length and might be more suscepti-
ble to injuries or fractures (Mueller
et al., 1994). One of the reasons
for these complications is nerve
damage, which might accompany
diabetes (Rojas et al., 2018). In
our study, we showed that a single
i.t. and i.p. injection of C021
improved the locomotor activity of
STZ-treated animals, which we
could observe by prolonged persis-
tence on rotating rods. All the
results we obtained suggest that
CCR4 is an important target for
diabetic neuropathy management;
however, the exact molecular
mechanism needs future
investigation.
Given the high prevalence of
pain experienced by diabetic
patients and the fact that
chemokine and opioid receptors
may crosstalk, we found it
essential to know whether the
blockade of CCR4 can influence
opioid effectiveness. It is known
from clinical (Przeklasa-
Muszynska and Dobrogowski,
2011) and experimental (Zurek
et al., 2001; Zychowska et al.,
2013a, 2017; Rojewska et al.,
2018) studies that diabetic neuro-
pathic pain management is not
easy due to the relatively low effec-tiveness of opioids against this pain. Many studies, includ-
ing these regarding diabetes, suggest that altered
neuroimmunological interactions are responsible for
weaker opioid analgesia. In models of neuropathic pain
of different etiologies, it has been shown that pronocicep-
tive interleukins (IL-1beta, IL-6, and IL-18) (Zanjani et al.,
2006; Mika, 2008; Chen et al., 2012; Pilat et al., 2015,
2016) and chemokines (CCL1, CCL2, CCL3, CCL4,
CCL5, CCL7, CCL9, CCL17 and CCL22) (Kwiatkowski
et al., 2016, 2019; Zychowska et al., 2017; Rojewska
et al., 2018; Bogacka et al., 2020) are involved in this phe-
nomenon. Moreover, the literature data give many evi-
dences that some of these cytokines also decrease the
analgesic effects of opioids (Szabo et al., 2002; Chen
et al., 2007; Pilat et al., 2015, 2016; Zychowska et al.,
2017; Kwiatkowski et al., 2019; Pawlik et al., 2020). Addi-
tionally, beneficial effects of immunomodulators and glial
inhibitors, such as pentoxyphylline and minocycline, on
opioid effectiveness in neuropathy have already been
shown (Mika et al., 2013; Zychowska et al., 2013a,
2016; Rojewska et al., 2014; Piotrowska et al., 2016b).
These studies have indicated that the effectiveness of
mentioned substances is due to their beneficial effects
on microglia cells, which are strongly activated in
neuropathy (Ferrini et al., 2013; Mika et al., 2013;
Kwiatkowski and Mika, 2018). As we mention, our
Fig. 6. The single intraperitoneal injection of C021 enhanced the effectiveness of morphine and
buprenorphine 7 days after STZ treatment in mice. Animals treated with a single injection of V or C021
(10 mg/kg) received a single dose of V, M (5 mg/kg) or B (5 mg/kg) after 30 min, and 30 min later, the
behavioral tests were conducted. Data are presented as the mean ± SEM, total number of animals:
51 mice: (B, C) n= 7–8 mice per group; (D, E) n= 5–7 mice per group. The results were analyzed
using one-way ANOVA with Bonferroni’s multiple comparisons test. **p< 0.01; ***p< 0.001 indicate
differences compared with the V + V-treated STZ-exposed mice; @p< 0.05; @@@p< 0.001 indicate
differences between the C021 + V- and C021 + M/B-treated STZ-exposed mice; ++p< 0.01;
+++p< 0.001 indicate differences between the V +M/B- and C021 + M/B-treated STZ-exposed
mice. Abbreviations: B; buprenorphine; C021, C021 dichydrochloride (CCR4 antagonist); M,
morphine; STZ, streptozotocin; V, water for injection.
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strong activation of microglia under
diabetic neuropathy (Zychowska
et al., 2013a). CCR4 expression
on microglia/macrophages was
recently suggested to be responsi-
ble for pro-inflammatory polariza-
tion of these cells (Chen et al.,
2019). This corresponds well with
our results showing, that in rats
after sciatic nerve ligation CCR4
blockade reduced the level of
microglia/macrophages in the
spinal cord and DRG (Bogacka
et al., 2020). Similarly, also antago-
nists of CCR2 (Kwiatkowski et al.,
2017) and CCR5 (Kwiatkowski
et al., 2016) enhanced morphine
analgesia in a nerve injury-
induced model of neuropathy by
reducing microglia/macrophages
level. Other data give evidence that
the CCL2, a key mediator of spinal
microglial activation, is likewise
responsible for lower opioid effi-
cacy in naive animals (Zhao et al.,
2012). This is in agreement with
our results showing that C021 pre-
vents CCL2 upregulation in mouse
model of neuropathy, which can be
one of the mechanism of its benefi-
cial effects (Bogacka et al., in
press). The data from our research
provide the first evidence that
intrathecal and intraperitoneal
injections of C021 enhanced the
effectiveness of morphine and
buprenorphine in diabetic neuropa-
thy. This is an important observa-
tion from a clinical point of view;
however, the molecular mecha-
nism still needs further investiga-
tions. Based on literature (Zhang
et al., 2003, 2004; Brack et al.,
2004; Chen et al., 2004; Heinisch
et al., 2011) we hypothesize that
crosstalk between opioid and che-
mokine receptors via heterologous
desensitization can be another rea-
son of decreased analgesic effect
of opioids. Heterologous desensiti-
zation is observed in cells that
express multiple types of GPCRs
when the activation of one type of
receptor leads to the changes of
other types due to activation of
several protein kinases (Kelly
et al., 1999; Zhang et al., 2004).
Moreover, activation of opioid
receptors by an agonist induces
changes in some chemokine levels
Fig. 7. The intrathecal and intraperitoneal injection of C021
beneficially affected motor coordination 7 days after STZ treat-
ment in mice. The effects of a single injection of V or C021 (30 lg/
5 ll i.t., A and 20 mg/kg i.p., B) were measured 1 h 15 min after V or
antagonist administration by the rotarod test. *p< 0.05 indicates
significant differences between the V-treated and C021-treated STZ-
exposed animals. Data are presented as the mean ± SEM, total
number of animals: 48 mice: (A, B) n= 8–12 mice per group.
##p< 0.01 indicates differences between the naive and the V-treated
STZ-exposed animals. Abbreviations: N, naive, V, water for injection;
C021, C021 dichydrochloride (CCR4 antagonist); STZ,
streptozotocin.
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Mahajan et al., 2002; Happel et al., 2008). Ligands which
bind to chemokine receptors can desensitize opioid
receptors, and by this mechanism decreases the opioid
analgesia. It has been already shown that chemokine
ligands e.g. CXCL12 and CCL5 induce the phosphoryla-
tion of MOR and influence the perception of pain by
cross-desensitizing of this opioid receptor (Szabo et al.,
2002). In 2014, Ye et al. described heterologous desensi-
tization between CXCR3-MOR, which results in suppress-
ing morphine analgesic effects (Ye et al., 2014). Others
have shown that morphine can increase CCR5 expres-
sion and that CCR5-MOR also may crosstalk with each
other by dimerization (Miyagi et al., 2000; Yuan et al.,
2012, 2013). Therefore, pharmacological targeting of het-
erodimers is a useful method to modulate opioid receptor
activity (Yuan et al., 2012, 2013; Akgün et al., 2015).
Recently, Akgün and coworkers synthesized bivalent
ligands (MCC series) that contain 2 pharmacophores (a
mu opioid agonist and a CCR5 antagonist), which dimin-
ished inflammation-induced pain-related behavior; this
synthesis is an interesting therapeutic strategy (Akgün
et al., 2015). However, the CCR5 antagonist has no anal-
gesic properties in streptozotocin-induced neuropathy
(Rojewska et al., 2018); therefore, we suggest that for dia-
betes therapy, the creation of bivalent ligands that contain
MOR agonist and CCR4 antagonist pharmacophores
would be more valuable.
Our results are worth emphasizing because we
provide the first evidence that CCR4 antagonists can
enhance morphine and buprenorphine analgesia in
neuropathic pain, which may be relevant for clinical
applications in the future. Equally important are the data
showing that CCR4 blockade is also beneficial for
wound healing in diabetes (Barros et al., 2019). From a
clinical perspective it is worth to point out that in our micemodel of diabetes-induced neuropathic pain we did not
observed any side effects in C021 (CCR4 antagonist)
treated animals and, what is very important, mice have
revealed reduced tactile and thermal hypersensitivity.
Our behavioral tests also showed that CCR4 antagonist
has positive impact on motor coordination of animals. It
is known that any drug or substance can induce some
side effects. This cannot also be ruled out for CCR4 tar-
geted drugs. Due to the fact that CCR4 is expressed by
Th2 and Treg cells, it become potential therapeutic point
for treatment of allergic diseases such as asthma and ato-
pic dermatitis, as well as Adult T-cell leukemia/lymphoma
(ATL) (Yoshie and Matsushima, 2015). The pharmaceuti-
cal company Kyowa Hakko Kirin, developed fully human-
ized monoclonal antibody targeting CCR4, named
Mogamulizumab (Yu et al., 2017). During I and II phase
of clinical trials in patients with ATL this antibody was
well-tolerated, but in few cases induced skin-related
adverse effects, which might be correlated with almost
total absence of Treg cells (Ishida et al., 2013). Therefore,
in order to determine if and what side effects CCR4-
oriented therapy can bring under diabetic neuropathy,
we definitely need a long studies involving both animal
and human ones. Moreover, the gender-related differ-
ences need to be study, especially since females often
have more serious complications during diabetes
(Centers for Disease Control and Prevention, 2018).
Overall, these data emphasized CCR4 as a promising tar-
get to be exploited as a novel therapeutic approach for the
polytherapy of diabetic-based neuropathic pain.
In conclusion, diabetic neuropathy is a serious and
common complication of diabetes that is associated with
increased risks of mortality and cardiovascular diseases.
In light of our current results, we can confidently state
that CCR4 signaling plays an important role in a mouse
model of diabetic neuropathy. These findings support
the hypothesis that the blockade of CCR4 signaling has
a positive feedback role in the regulation of morphine
and buprenorphine analgesia. Therefore, blocking CCR4
may represent a new strategy for effective polytherapy
with opioids, which may provide a rational strategy in
patients suffering from diabetic neuropathic pain.ACKNOWLEDGMENTS
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